New combo aims to shrink spleen and ease symptoms in Hard-to-Treat myelofibrosis
NCT ID NCT06414681
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This early-phase trial tests two drugs, tagraxofusp and pacritinib, together in about 20 adults with myelofibrosis (a bone marrow disorder) who have already tried standard JAK inhibitors or cannot take them. The main goals are to see if the combination can shrink an enlarged spleen and improve symptoms like fatigue and night sweats. The study also checks for side effects and how well patients tolerate the treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS (MF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Kansas Cancer Center
RECRUITINGFairway, Kansas, 66204, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.